info:eu-repo/semantics/article
Stealth nanocarriers based sterosomes using PEG post-insertion process
Fecha
2017-06Registro en:
Cieślak, Anna; Wauthoz, Nathalie; Nieto Orellana, Alejandro; Lautram, Nolwenn; Béjaud, Jérôme; et al.; Stealth nanocarriers based sterosomes using PEG post-insertion process; Elsevier Science; European Journal Of Pharmaceutics And Biopharmaceutics; 115; 6-2017; 31-38
0939-6411
CONICET Digital
CONICET
Autor
Cieślak, Anna
Wauthoz, Nathalie
Nieto Orellana, Alejandro
Lautram, Nolwenn
Béjaud, Jérôme
Hureaux, José
Lafleur, Michel
Benoit, Jean-Pierre
Salomon, Claudio Javier
Bastiat, Guillaume
Resumen
Sterosomes (STEs), a new and promising non-phospholipidic liposome platform based on palmitic acid (PA) and cholesterol (Chol) mixtures, need to have polyethylene glycol (PEG) chains grafted to their surface in order to obtain long-circulating nanocarriers in the blood stream. A post-insertion method was chosen to achieve this modification. The post-insertion process of PEG-modified distearoylphosphoethanolamine (DSPE-PEG) was monitored using the zeta potential value of STEs. Various conditions including PEG chain length and the DSPE-PEG/PA-Chol ratio, were explored. Zeta potential of STEs changed from about −40 mV for non-modified STEs to values close to 0 mV by the end of the process, i.e. for PEG-modified STEs. The kinetics of DSPE-PEG insertion and the stability of the resulting PEG-modified STEs were not considerably influenced, within the investigated range, by changes in PEG chain lengths and in DSPE-PEG/PA-Chol proportion. The post-insertion of PEG chains reduced in vitro complement activation as well as in vitro macrophage uptake compared to the non-modified STEs. Moreover, longer blood circulation time in mice was established for PEG-modified STEs intravenously injected compared to non-modified STEs. These results establish that post-insertion process of PEG chains to STEs is a promising strategy for developing long-term circulating drug delivery nanocarriers.